CDK4/6 Inhibitors Impede Chemoresistance and Inhibit Tumor Growth of Small Cell Lung Cancer
Advanced Science · 2024
DOI: 10.1002/advs.202400666 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2024. Verfasst von Yang Wen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Zhujiang Hospital, Southern Medical University, Guangzhou, 510080, China. Hauptthemen laut MEDLINE: Small Cell Lung Carcinoma, Lung Neoplasms, Cyclin-Dependent Kinase 4, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Clinical Research Initiative Project of Southern Medical University, Science and Technology Planning Project of Guangdong Province, China.
Abstract (Originalsprache)
Small cell lung cancer (SCLC) is characterized by rapid development of chemoresistance and poor outcomes. Cyclin‐dependent kinase 4/6 inhibitors (CDK4/6is) are widely used in breast cancer and other cancer types. However, the molecular mechanisms of CDK4/6 in SCLC chemoresistance remain poorly understood. Here, Rb1 flox/flox , Trp53 flox/flox , Pten flox/flox (RTP) and Rb1 flox/flox , Trp53 flox/flox , Myc LSL/LSL (RPM) spontaneous SCLC mouse models, SCLC cell line‐derived xenograft (CDX) models, and SCLC patient‐derived xenograft (PDX) models are established to reveal the potential effects of CDK4/6is on SCLC chemoresistance. In this study, it is found that CDK4/6is palbociclib (PD) or ribociclib (LEE) combined with chemotherapeutic drugs significantly inhibit SCLC tumor growth. Mechanistically, CDK4/6is do not function through the classic Retionblastoma1 (RB) dependent axis in SCLC. CDK4/6is induce impair autophagy through the AMBRA1‐lysosome signaling pathway. The upregulated AMBRA1 protein expression leads to CDK6 degradation via autophagy, and the following TFEB and TFE3 nuclear translocation inhibition leading to the lysosome‐related genes levels downregulation. Moreover, it is found that the expression of CDK6 is higher in SCLC tumors than in normal tissue and it is associated with the survival and prognosis of SCLC patients. Finally, these findings demonstrate that combining CDK4/6is with chemotherapy treatment may serve as a potential therapeutic option for SCLC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Zhujiang Hospital, Southern Medical University, Guangzhou, 510080, China.
- Department of Pathology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, 510180, China.
- Department of Pathology, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, 510180, China.
- Department of Oncology, Fujian Provincial Hospital, Fuzhou, 350001, China.
- Department of Radiation Oncology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, China.
- Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, 510080, China.
ORCID-Profile: Yang Wen
Förderung
- National Natural Science Foundation of China
- Clinical Research Initiative Project of Southern Medical University
- Science and Technology Planning Project of Guangdong Province, China
- Science and Technology Program of Guangzhou
- Guangzhou Science and Technology Project
- Guangdong Natural Science Foundation
- Young and Middle-aged Talents Training Project of Fujian Provincial Health Commission
- Natural Science Foundation of Guangdong Province
Zitieren
APA
Wen, Y., Sun, X., Zeng, L., Liang, S., Li, D., Chen, X., Zeng, F., Zhang, C., Wang, Q., Zhong, Q., Deng, L., & Guo, L. (2024). CDK4/6 Inhibitors Impede Chemoresistance and Inhibit Tumor Growth of Small Cell Lung Cancer. Advanced Science. https://doi.org/10.1002/advs.202400666
Vancouver
Wen Y, Sun X, Zeng L, Liang S, Li D, Chen X, et al. CDK4/6 Inhibitors Impede Chemoresistance and Inhibit Tumor Growth of Small Cell Lung Cancer. Advanced Science. 2024. doi:10.1002/advs.202400666
BibTeX
@article{Wen2024,
author = {Wen, Yang and Sun, Xue and Zeng, Lingge and Liang, Shumei and Li, Deyu and Chen, Xiangtian and Zeng, Fanrui and Zhang, Chao and Wang, Qiongyao and Zhong, Qinsong and Deng, Ling and Guo, Linlang},
title = {CDK4/6 Inhibitors Impede Chemoresistance and Inhibit Tumor Growth of Small Cell Lung Cancer},
journal = {Advanced Science},
year = {2024},
doi = {10.1002/advs.202400666}
}
EUVIMED